Document Information:

Device Name: ReActiv8® System

Document/Label Type: Clinical Summary

Country: US

Language: English

Revision: A

Filename: ReActiv8® System-Clinical Summary- US-English- Rev A.pdf

ReActiv8®

Clinical Summary

Mainstay Medical

ReActiv8 Clinical Summary

A. Executive Summary

The study was an international, multi-center, prospective, randomized, double-blind, active-sham controlled blinded trial comparing the ReActiv8 System (patient appropriate stimulation level – Treatment Group) to an active sham (ReActiv8 programmed to deliver low level stimulation – Control Group). Although the primary efficacy endpoint was inconclusive at the 120-day visit, the totality of evidence provides compelling support in favor of the treatment. The prespecified cumulative proportion of responder analysis of the primary endpoint data (ITT) showed that the difference between the Treatment and Control group was statistically significant (p=0.0499).

Patients in the trial had an average CLBP duration of 14 years and suffered pain on 97% of the days in the year prior to enrolment. The overall results demonstrated that patients moved from severe pain and borderline severe disability to mild pain and disability. Benefits which emerged in favor of the treatment within the blinded phase continued to grow through the two-year visit, demonstrating durability of the gained improvements and corroborating the rehabilitative nature of the treatment. The reversal of trajectory and subsequent substantial and significant improvements documented in the Control group post crossover at 120 days, provides further support in favor of ReActiv8 treatment efficacy.

Clinically meaningful and durable improvements were consistently demonstrated across all outcome measures and 60% of patients who were on opioids at baseline, had discontinued or reduced their use by the two-year visit.

Given the public health concern over the chronic use of opioids, physicians and patients are looking for non-opioid options for treating pain, and this data supports that ReActiv8 is a safe, effective and durable nondrug treatment option for mechanical CLBP.

The consistent clinically meaningful benefits across all outcome measures, the favorable safety profile and positive impact on opioid reduction demonstrated in this trial, leads to a favorable benefit/risk ratio for use of this therapy in severely impacted patients with refractory mechanical CLBP.

B. Background

The ReActiv8-B Trial, conducted under an investigational device exemption (IDE), provided the evidence of safety and effectiveness of ReActiv8 therapy in the management of intractable chronic low back pain associated with multifidus muscle dysfunction. Data from this trial were

the basis for PMA approval.

C. Study Design

The study was an international, multi-center, prospective, randomized, double-blind, active-sham controlled blinded trial comparing the ReActiv8 System (patient appropriate stimulation level – Treatment Group) to an active sham (ReActiv8 programmed to deliver low level stimulation – Control Group).

Between September 13, 2016 and June 14, 2018, 561 patients were enrolled at 26 investigational sites. A total of 204 patients met all enrollment criteria and were randomized in a 1:1 ratio to the treatment and control groups. After the primary endpoint at 120-days, patients randomized to the Control Group were allowed to crossover to receive stimulation at a therapeutic level. Patients continue to be followed annually for five years.

Many rigorous methods were incorporated in the design and implementation of the trial. These methods are in line with the emerging quality standards as discussed at the Initiative on Methods, Measurement, and Pain Assessments in Clinical Trials (IMMPACT) XXII November 2018 meeting. As such, the quality of the methods used in this trial are higher than that seen in many trials of implantable neurostimulation devices for chronic pain, including various types of CLBP. Prospectively defined actions demonstrating the sponsor's commitment to conducting a high-quality trial include the following:

- Minimization of bias
    - Randomized, controlled trial
        - Randomization post implant
        - Active sham control
    - Blinded
        - Patients
        - Investigator and site personnel
        - Sponsor
        - Oversight committees
        - Monitors
    - Maintained equipoise
        - Balanced interactions with both treatment groups,
        - Setting of neutral expectations
    - Outcome data collected prior to interaction with the patient and prior to programming
    - Rigorous screening process, including review by independent physician experts
- Independent trial oversight

    - Independent, blinded physician experts on several committees
        - Data Monitoring Committee (DMC)
        - Clinical Events Committee (CEC)
        - Baseline MRI Review by independent orthopedic spine surgeons
        - Overview of inclusion/exclusion criteria by Study Chair Principal Investigator
    - Independent statisticians
- Early and frequent monitoring
- Comprehensive training, including a requirement for up-to-date Good Clinical Practice (GCP) training for all site personnel involved in the trial
- Minimization of financial conflict of interest

1. Key Enrollment Criteria

Enrollment in the ReActiv8-B trial was limited to patients who met the following key *inclusion* criteria:

- Age ≥22 years, ≤75 years
- 7-day recall of average Low Back Pain VAS of ≥6.0 cm and ≤9.0 cm at baseline
- Oswestry Disability Index score ≥21% and ≤60% at the baseline visit
- Chronic Low Back Pain that has persisted >90 days prior to the baseline visit, and which has resulted in pain in at least half of the days in the 12 months prior to the baseline visit.
- Evidence of lumbar multifidus muscle dysfunction by the Prone Instability Test
- Continuing low back pain despite >90 days of medical management including at least one attempt of physical therapy treatment and attempted medications for low back pain.

Patients were not permitted to enroll in the ReActiv8-B Trial if they met any of the following key *exclusion* criteria:

- Body mass index (BMI) >35
- Back pain characteristics, such as: any surgical correction procedure for scoliosis at any time or a current clinical diagnosis of moderate to severe scoliosis (>25 degree cobb angle), severe lumbar spine stenosis in patients with lower extremity pain, and pathology seen on MRI that is clearly identified and is likely the cause of the CLBP that is amenable to surgery.
- Leg pain described as being worse than back pain, or radiculopathy below the knee.
- Surgical or other procedures exclusions, such as: any previous rhizotomy within one year prior to the baseline visit, anesthetic block or injections at or

below the T8 vertebra in the 30 days prior to the baseline visit, or any previous back surgery at or below segmental level T8, or spinal fusion at any level.

- Any comorbid chronic pain conditions.
- Have an assessment of current active depression significant enough to impact perception of pain, compliance with intervention, and/or ability to evaluate treatment outcome.
- Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.
- Any other active implantable device.
- A condition currently requiring or likely to require use of MRI or diathermy while implanted with the ReActiv8.

Follow-up Schedule

Patients who met the enrollment criteria, proceeded to the ReActiv8 system implant. Once implanted, the patients were randomized to one of the two study groups at 14 days post-implant and stimulation programmed accordingly based on the randomization. Patients returned for visits at 14 days, 45 days, 75 days, 120 days, 180 days, 240 days and one-year post randomization/activation of the ReActiv8 system and annually thereafter for a minimum of 5 years.

The assessments required at each visit are shown in Table 1 below. Adverse events were collected at every visit beginning at enrollment.

Table 1: Study Assessment Timepoints

Study Requirement	Enrollment & Baseline	ReActiv8 Implant	Randomization & Activation	14 Day Visit	45 Day Visit	75 Day Visit	Primary Endpoint: 120 Day Visit	180 Day Visit	240 Day Visit	Annual Follow-up
Screening	✓									
ODI	✓					✓	✓	✓	✓	✓
Back Pain VAS (Journal)	✓				✓	✓	✓			
Back Pain VAS (Single Point)	✓			✓	✓	✓	✓	✓	✓	✓
Medications Questionnaire	✓	✓			✓	✓	✓	✓	✓	✓
EQ-5D	✓					✓	✓	✓	✓	✓
$DASS_{21}$	✓									
Low Back Pain Descriptive Characteristics	✓				✓	✓	✓	✓	✓	✓
Work Status Evaluation	✓				✓	✓	✓	✓	✓	✓
Percent Pain Relief (PPR)						✓	✓	✓	✓	✓

Subject Global Impression of Change (SGIC)						✓	✓	✓	✓	✓
Treatment Satisfaction Questionnaire (TSQ)						✓	✓	✓	✓	✓
Clinical Global Impression (CGI)						✓	✓	✓	✓	✓
Health Care Utilization	✓							✓	✓	✓
Blinding Assessment Questionnaire							✓			
X-Ray (AP and Lateral)		✓		✓						
Device Measurements & Stimulation thresholds		✓	T	T	T	T	T	✓	✓	✓
Interrogate IPG for lead impedance & compliance				✓	✓	✓	✓	✓	✓	✓
Physical Exam & Surgical Site Exam	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Adverse Events		✓	✓	✓	✓	✓	✓	✓	✓	✓
Pregnancy Test	✓									

✓= Required for all patients; T=Required for Treatment Group Only (Control Group – programming performed but no stimulation thresholds checked)

2. Clinical Endpoints

Primary Efficacy Endpoint

The primary efficacy endpoint is a comparison of responder rates between the Treatment group and the Control group at the 120-day visit, where a "responder" is defined as a patient with ≥30% reduction from baseline in a 7-day recall of average low back pain VAS without any increase from baseline in pain medication and/or muscle relaxants prescribed and taken in the two weeks prior to the visit. Per the IMMPACT guidelines, a reduction of 30% is considered a clinically meaningful reduction.

Patients were also asked at each follow-up visit if he/she had taken any new prescribed pain medications or had a dose change for any prescribed medications in the two weeks prior to the visit. Any increase in pain medications in the two weeks prior to the 120-day visit was considered a significant change in medications for the purposes of the primary endpoint. Rescue medications taken on an exceptional basis for acute pain conditions other than back pain were also documented and their impact on the estimated treatment effect examined.

Components of the Primary Efficacy Endpoint

The individual components of the primary efficacy endpoint (VAS and medications) were also analyzed and presented separately.

VAS

VAS was analyzed using the following additional methods:

- The mean change in VAS was calculated and compared between the Treatment group and Control group

- The cumulative proportion of responder curves (i.e., cumulative distribution functions) were constructed for each treatment group separately, overlaid, and compared. This analysis compares patient responses, measured by change in VAS, across each possible threshold change level rather than dichotomizing the responses at the single cut point of 30% reduction in VAS.

Pain Medications

Records of pain medications were collected along with all other medications used for treatment of low back pain, which were also being collected for analysis of secondary and cost-effectiveness endpoints. At each scheduled follow-up visit, patients reported medications taken. Rescue medications taken on an exceptional basis for acute pain conditions other than back pain were also documented.

In a supplementary analysis, prespecified in the clinical protocol and statistical analysis plan (SAP) prior to the start of the trial, patients found to have taken medications for reasons other than back pain were excluded to evaluate the potential impact on estimates of treatment group differences.

Primary Safety Assessment

The primary safety assessment evaluated serious device- and/or procedure-related adverse events in all patients in the Intent to Treat cohort at the 120-day visit. All reported adverse events were documented and reported with summary statistics presented for observed rates.

Secondary Endpoints

The following secondary endpoints were evaluated:

a. Comparison of change from baseline in Oswestry Disability Index (ODI) between Treatment and Control groups at the 120-day visit.
b. Comparison of change from baseline in EQ-5D between Treatment and Control groups at the 120-day visit.
c. Comparison of Percent Pain Relief (PPR) between Treatment and Control groups reported by the patient at the 120-day visit.
d. Comparison of Subject Global Impression of Change (SGIC) between Treatment and Control groups at the 120-day visit.
e. Comparison of proportion of patients with Resolution of Low Back Pain (defined as a VAS score ≤ 2.5 cm) between Treatment and Control groups at the 120-day visit.
f. Evaluation of changes in primary and secondary efficacy metrics in the Crossover group following the 120-day visit.

D. Accountability of PMA Cohort

At the time of the database lock for the PMA report, there were 561 patients enrolled in the IDE study, of those 204 patients met the inclusion criteria and had the ReActiv8 system implanted. At the randomization visit 14 days after implant, 102 patients were randomized to the Treatment group and 102 patients were randomized to the Control group. A total of 200 patients in the Treatment group and 201 in the Control group returned for the primary endpoint visit at 120 days. A total of 176 patients have completed the one-year follow-up, and 156 have completed the two-year follow-up. See Figure 1 below.



LTFU: Lost to follow-up
Missed Visit: Includes scheduling difficulties, noncompliance, and safety reasons (e.g., broken ankle)
To account for the timing of withdrawal, patients count only once within the time interval in which they were withdrawn

Figure 1: Patient Disposition by Visit through Two Years

E. Study Population Demographics and Baseline Parameters

The demographics of the study population are typical for a pain study. The study groups were well balanced across all factors with the exception of previous rhizotomy. Of the 12% of patients who had one or more previous rhizotomy, a higher percentage of patients in the Control Group had a previous rhizotomy compared to the Treatment group (17% and 8%, respectively). Since the enrollment criteria required that the previous rhizotomy had to have been >12 months prior to enrollment, history of a previous rhizotomy was not expected to impact the study results. See Table 2.

Table 2:Medical History and Baseline Demographics

Characteristic	Treatment N=102 Mean ± SD (Min, Max) or n (%)	Control N=102 Mean ± SD (Min, Max) or n (%)	Total N=204 Mean ± SD (Min, Max) or n (%)	p-value[1]
Age (years)	46 ± 10 (22, 66)	48 ± 9 (26, 71)	47 ± 9 (22, 71)	0.140
Gender				
Female	56 (55%)	54 (53%)	110 (54%)	0.779
Male	46 (45%)	48 (47%)	94 (46%)	
BMI	28 ± 4 (19, 35)	28 ± 4 (17, 40)	28 ± 4 (17, 40)	0.707
Race				
White or Caucasian	96 (94%)	96 (94%)	192 (94%)	1.000
Black or African American	3 (3%)	3 (3%)	6 (3%)	
American Indian or Alaskan Native	1 (1%)	0 (0%)	1 (0%)	
Asian	1 (1%)	1 (1%)	2 (1%)	
Native Hawaiian or other Pacific Islander	0 (0%)	0 (0%)	0 (0%)	
Other	1 (1%)	2 (2%)	3 (1%)	
Ethnicity – Hispanic/Latino	4 (4%)	5 (5%)	9 (4%)	0.748
Pain duration (years from onset of the 1st occurrence)	14.4 ± 10.8 (1.0, 49.7)	13.9 ± 10.4 (0.6, 44.1)	14.2 ± 10.6 (0.6, 49.7)	0.736
Percent of Days with LBP	97 ± 8 (60, 100)	97 ± 8 (58, 100)	97 ± 8 (58, 100)	0.703
Leg Pain	32 (31%)	30 (29%)	62 (30%)	0.761
Associated with back pain	28 (88%)	25 (83%)	53 (85%)	0.728
Side				
Both	10 (31%)	9 (30%)	19 (31%)	0.744
Left	11 (34%)	9 (30%)	20 (32%)	
Right	11 (34%)	12 (40%)	23 (37%)	
Number of Prior PT Sessions	30 ± 39 (1, 300)	32 ± 63 (1, 600)	31 ± 52 (1, 600)	0.758

Characteristic	Treatment N=102 Mean ± SD (Min, Max) or n (%)	Control N=102 Mean ± SD (Min, Max) or n (%)	Total N=204 Mean ± SD (Min, Max) or n (%)	p-value[1]
Previous Rhizotomy	8 (8%)	17 (17%)	25 (12%)	0.055
Months from Most Recent Rhizotomy	62.7 ± 126.5 (12.0, 375.2)	35.8 ± 33.5 (12.0, 147.7)	44.4 ± 74.7 (12.0, 375.2)	0.414
Previous Injection Procedure	53 (52%)	46 (45%)	99 (49%)	0.327
Number of Prior Injections	2.6 ± 1.8 (1.0, 9.0)	2.7 ± 2.6 (1.0, 12.0)	2.6 ± 2.2 (1.0, 12.0)	0.981
History of Depression	32 (31%)	38 (37%)	70 (34%)	0.376
Current, Active Depression	7 (7%)	11 (11%)	18 (9%)	0.323
Use of Pain Medication at Baseline	77 (75%)	85 (83%)	162 (79%)	0.166
Use of Opioid Containing Medication at Baseline	36 (35%)	40 (39%)	76 (37%)	0.562

[1] p-values are Chi-square (or Fisher's Exact as appropriate) for binary parameters, Cochran-Mantel-Haenszel for multi-level parameters and ANOVA for continuous variables.

F. Safety and Effectiveness Results

1. Safety Results

The analysis of safety was based on the ITT population which included 102 in the Treatment group and 102 in the Control group for a total of 204 patients implanted. Of the 204 patients, 201 patients returned for the primary endpoint visit at 120 days with 156 patients out to two years post activation of the ReActiv8 System.

The key safety outcome for this study was assessment of any serious device or procedure-related adverse events reported by the 120-day visit. All adverse events were also documented and reported in the summary statistics including the observed rates through the two-year visit.

Among the 204 randomized patients, 8 serious adverse events (SAEs) related to the device/procedure were reported in 8 patients (3 in the Treatment group and 5 in the Control group) for an overall related serious adverse event rate of 4% at the 120-day primary endpoint visit. See Table 3 below. There were no unanticipated SAEs related to the device or procedure.

No further serious adverse events that are related to the device/procedure have been reported post the 120-day visit throughout the study.

Table 3: Serious Device or Procedure-Related Event through Day 120

	Treatment N=102		Control N=102		Total N=204	
Adverse Event	**AE # Events (Pt, %Pt)**	**Number Resolved /Total**	**AE # Events (Pt, %Pt)**	**Number Resolved /Total**	**AE # Events (Pt, %Pt)**	**Number Resolved /Total**
Related Total SAEs	**3 (3, 3%)**	**3/3**	**5 (5, 5%)**	**4/5**	**8 (8, 4%)**	**7/8**
Implant site pocket infection	2 (2, <2%)	2/2	4 (4, 4%)	4/4	6 (6, 3%)	6/6
Intra-procedural upper airway obstruction	1 (1, <1%)	1/1	0	0/0	1 (1, <1%)	1/1
Numbness in leg (non-radicular)	0	0/0	1 (1, <1%)	0/1	1 (1, <1%)	0/1

A total of 13 serious unrelated adverse events occurred during the study as shown in Table 4. All events were reviewed by the CEC and adjudicated as not related. Twelve of the adverse events resolved. The patient with a malignant Stage IV melanoma was withdrawn from the study to focus on treatments for the cancer diagnosis. This event remained ongoing at the time of patient withdrawal but was closed for study purposes.

Table 4: Serious Unrelated Events through Two Years

	Treatment N=102		Control N=102		Total N=204	
Adverse Event	**AE # Events (Pt, % Pt)**	**Number Resolved/ Total**	**AE # Events (Pt, % Pt)**	**Number Resolved/ Total**	**AE # Events (Pt, % Pt)**	**Number Resolved/ Total**
Total Unrelated	**6 (6, 6%)**	**5/6**	**7 (7, 7%)**	**7/7**	**13 (13, 6%)**	**12/13**
Acute appendicitis	2 (2, 2%)	2/2	0	0/0	2 (2, <1%)	2/2
Ankle fracture	1 (1, <1%)	1/1	0	0/0	1 (1, <1%)	1/1
Cellulitis	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
Chest pain	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
Concussion	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
Gallstones	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
Malignant melanoma stage IV	1 (1, <1%)	0/1	0	0/0	1 (1, <1%)	0/1
Meningitis	1 (1, <1%)	1/1	0	0/0	1 (1, <1%)	1/1
Myocardial infarction	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
Non ST segment elevation myocardial infarction	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
Stomach cancer	0	0/0	1 (1, <1%)	1/1	1 (1, <1%)	1/1
TIA	1 (1, <1%)	1/1	0	0/0	1 (1, <1%)	1/1

As summarized in Table 5, a total of 611 adverse events (166 events [27%] were related and 445 events (73%) were unrelated) were reported within two years. Of these, 8 were serious and related and 13 were serious and unrelated. Of those that

were related, 61% occurred in the first 120 days after implant, which includes events that can happen with any surgical procedure. Of the related events, 84% have resolved.

When adjudicating events, if there was any uncertainty regarding relatedness, the CEC adjudicated the event as related.

Table 5: Overall Summary of Adverse Events Through Two Years

	Overall		
AE Category	**Treatment # Events (% Events)**	**Control # Events (% Events)**	**Total # Events (% Events)**
Overall	**307**	**304**	**611**
By Seriousness			
Serious Adverse Events	9 (3%)	12 (4%)	21 (3%)
Related	3 (1%)	5 (2%)	8 (1%)
Unrelated	6 (2%)	7 (2%)	13 (2%)
Non-Serious Adverse Events	298 (97%)	292 (96%)	590 (97%)
Related	72 (23%)	86 (28%)	158 (26%)
Unrelated	226 (74%)	206 (68%)	432 (71%)
By Relatedness			
Related[1]	75 (24%)	91 (30%)	166 (27%)
Device	23 (7%)	32 (11%)	55 (9%)
Procedure	35 (11%)	39 (13%)	74 (12%)
Stimulation	18 (6%)	22 (7%)	40 (7%)
Unrelated	232 (76%)	213 (70%)	445 (73%)
By Outcome			
Resolved	239 (78%)	235 (77%)	474 (78%)
Not Resolved	68 (22%)	69 (23%)	137 (22%)

[1] 3 events were adjudicated by the CEC as possibly related to the device and possibly related to stimulation. Therefore, the sum of the relatedness categories does not add up to the total number of related events

Deaths

There has been one unrelated death reported in the ReActiv8-B trial, which occurred approximately three years after enrollment.

All Study Related Adverse Events

Table 6 provides a summary of all study-related adverse events (both serious and non-serious) by treatment group through 120 days. After the 120-day visit the control patients elected to receive stimulation at a therapeutic level; therefore, both patient groups are summarized together through the two-year visit. Events that could occur with any surgical procedure and were not specific to receiving an implantable device, are also listed in the table below the thick horizontal line.

Table 6: Study Related Adverse Events through Two Years

				Treatment Groups Combined			
	0-120 Days			121 Days – 1 Year	1 Year – 2 Years		
Event	Treatment N=102 # Events (Pt, % Pt)	Control N=102 # Events (Pt, % Pt)	Total N=204 # Events (Pt, % Pt)	Total N=204 # Events (Pt, % Pt)	Total N=170 # Events (Pt, % Pt)	Total N=204 # Events (Pt, % Pt)	Number Resolved/ Total
Related	**51 (37, 36%)**	**50 (35, 34%)**	**101 (72, 35%)**	**47 (32, 16%)**	**18 (14, 8%)**	**166 (102, 50%)**	**139/166 (84%)**
Implant site pocket pain	12 (11, 11%)	11 (11, 11%)	23 (22, 11%)	14 (9, 4%)	8 (5, 3%)	45 (36, 18%)	34/45
Device overstimulation of tissue	7 (7, 7%)	0	7 (7, 3%)	19 (17, 8%)	3 (3, 2%)	29 (27, 13%)	25/29
Lead conductor fracture	2 (2, 2%)	0	2 (2, <1%)	4 (4, 2%)	3 (3, 2%)	9 (9, 4%)	9/9
Implant site pocket infection	2 (2, 2%)	4 (4, 4%)	6 (6, 3%)	0	0	6 (6, 3%)	6/6
Back pain aggravated	1 (1, <1%)	3 (3, 3%)	4 (4, 2%)	0	1 (1, <1%)	5 (5, 2%)	3/5
Medical device discomfort	1 (1, <1%)	1 (1, <1%)	2 (2, <1%)	1 (1, <1%)	0	3 (3, 1%)	3/3
Coccyx pain	0	1 (1, <1%)	1 (1, <1%)	1 (1, <1%)	0	2 (2, <1%)	2/2
Numbness in leg	1 (1, <1%)	1 (1, <1%)	2 (2, <1%)	0	0	2 (2, <1%)	1/2
Neuropathic pain	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	0/1
Paresthesia lower limb	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Radicular pain	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	0/1
Sciatica	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Medical device site injury	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Facial paresthesia	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Headache	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Medical device site reaction	0	0	0	1 (1, <1%)	0	1 (1, <1%)	1/1
Shoulder pain	0	0	0	1 (1, <1%)	0	1 (1, <1%)	1/1
Throat sore	0	0	0	1 (1, <1%)	0	1 (1, <1%)	1/1
Buttock pain	0	0	0	1 (1, <1%)	0	1 (1, <1%)	0/1
Groin pain	0	0	0	1 (1, <1%)	0	1 (1, <1%)	0/1
Implant site warmth	0	0	0	0	1 (1, <1%)	1 (1, <1%)	0/1
Wound pain	3 (3, 3%)	3 (3, 3%)	6 (6, 3%)	0	1 (1, <1%)	7 (7, 3%)	6/7
Implant site dermatitis	2 (2, 2%)	2 (2, 2%)	4 (4, 2%)	1 (1, <1%)	0	5 (5, 2%)	5/5
Implant site hematoma	2 (2, 2%)	2 (2, 2%)	4 (4, 2%)	1 (1, <1%)	0	5 (5, 2%)	5/5
Implant site inflammation	3 (3, 3%)	1 (1, <1%)	4 (4, 2%)	0	0	4 (4, 2%)	4/4
Implant site paresthesia	0	2 (2, 2%)	2 (2, <1%)	1 (1, <1%)	0	3 (3, 1%)	3/3
Pain in hip	2 (2, 2%)	0	2 (2, <1%)	0	1 (1, <1%)	3 (3, 1%)	2/3
Allergic reaction to antibiotics	1 (1, <1%)	1 (1, <1%)	2 (2, <1%)	0	0	2 (2, <1%)	2/2
Implant site hypoesthesia	1 (1, <1%)	1 (1, <1%)	2 (2, <1%)	0	0	2 (2, <1%)	0/2
Postoperative nausea	1 (1, <1%)	1 (1, <1%)	2 (2, <1%)	0	0	2 (2, <1%)	2/2
Postoperative vomiting	2 (2, 2%)	0	2 (2, <1%)	0	0	2 (2, <1%)	2/2
Procedural vomiting	2 (2, 2%)	0	2 (2, <1%)	0	0	2 (2, <1%)	2/2
Vaginal yeast infection	1 (1, <1%)	1 (1, <1%)	2 (2, <1%)	0	0	2 (2, <1%)	2/2
Adverse drug reaction	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Anesthetic complication cardiac	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Bradycardia	1 (1, <1%)	0	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Calf pain	1 (1, <1%)	0	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Hypertrophic scar	1 (1, <1%)	0	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Implant site discharge	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Implant site erythema	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Implant site seroma	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Open wound	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Pharyngeal injury	1 (1, <1%)	0	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Post concussion syndrome	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Syncope vasovagal	0	1 (1, <1%)	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Upper airway obstruction	1 (1, <1%)	0	1 (1, <1%)	0	0	1 (1, <1%)	1/1
Unrelated	**79 (48, 47%)**	**68 (47, 46%)**	**147 (95, 47%)**	**191 (106, 52%)**	**107 (64, 38%)**	**445 (154, 75%)**	**335/445 (75%)**

There were 22% of the patients who underwent an additional surgical intervention through the two-year visit. In most cases, the need for an intervention (e.g., infection, lead replacement, IPG repositioning) was independent of the randomization assignment. A summary of these additional procedures is presented in Table 7 below.

A total of 9% of the patients underwent permanent system explant due to lack of efficacy, 3% due to pocket infection and 3% due to MRI required. One patient requested that the system be explanted because their pain was resolved, and one patient relocate away from the clinic. One additional patient that had a pocket infection was explanted and re-implanted after the infection resolved.

Table 7: Additional Surgical Procedures through Two Years

ReActiv8 Surgical Intervention	Treatment (N=102) Pt (% Pt)	Control (N=102) Pt (% Pt)	Total (N=204) Pt (% Pt)
Any ReActiv8 Surgical Intervention[1]	22 (22%)	23 (23%)	45 (22%)
System Explants	16 (16%)	16 (16%)	32 (16%)
Lack of Efficacy	*9 (9%)*	*9 (9%)*	*18 (9%)*
Infection[2]	*2 (2%)*	*4 (4%)*	*6 (3%)*
Need for MRI	*4 (4%)*	*2 (2%)*	*6 (3%)*
Pain Resolved	*1 (<1%)*	*0 (0%)*	*1 (<1%)*
Patient Relocation	*0 (0%)*	*1 (<1%)*	*1 (<1%)*
Lead Replacement	5 (5%)	5 (5%)	10 (5%)
IPG Repositioning	1 (1%)	4 (4%)	5 (2%)
Re-implant post-infection[2]	1 (1%)	0 (0%)	1 (0%)

[1] Patients may have had more than one procedure; therefore, the total does not equal the sum of the categories.
[2] One patient was re-implanted after the infection cleared.

Because the control group was an active sham control (ReActiv8), an assessment of the safety benefits would be better contextualized by comparing the safety profile of ReActiv8 while delivering treatment, to similar active implantable systems such as (SCS), even though the population is different.

When evaluating some of the more common risks with this type of procedure, the ReActiv8 safety profile compares favorably to that of SCS devices. One risk that notably did not occur in the ReActiv8-B trial is lead migration (Table 8).

Table 8: Safety Comparison of ReActiv8 to SCS Devices

Device/Procedural Events	SCS (Hayek[i]) Single Center Review 234 Patients	SCS (Eldabe[ii]) Literature Review >4000 Patients	ReActiv8-B Prospective 204 Patients
Adverse Events			
Infection	4.3%	2.5-10%	3%
Implant Related Pain	11.1%	9-12%	18%‡
Lead Fracture/Malfunction	4.3%	0-10.2%	4%
Lead Migration	8.5%	2-27%	0%
Surgical Interventions	48%	0-47%	20%
System Explants	23.9%	NA*	16%
Lead Replacement	23.9%	NA*	5%

* Detail not provided in the literature

‡ 28/36 (78%) resolved prior to the data cutoff: 18 resolved without surgical intervention;10 resolved with surgical intervention to reposition or remove the IPG.

The overall rate of safety events associated with ReActiv8 summarized below.

- The occurrence of adverse events was similar between the Treatment and Control groups.
- No lead migrations were reported.
- 84% of related adverse events resolved.
- 31% of the events can occur with any surgical procedure and are not specific to receiving an implantable device.

2. Effectiveness Results

Described below are the analyses that were performed per the protocol.

ITT: The intent to treat (ITT) analysis of effectiveness was based on 204 patients at the 120-day timepoint for the primary endpoint. Three patients did not return for the primary endpoint visit (2 in the treatment group and 1 in the control group) so their primary endpoint data was imputed.

Completers Cohort: All secondary and supporting analyses used the completers cohort analyses which are those patients who have a value for a given measurement at baseline and at the follow-up visits.

Crossover Cohort: After the primary endpoint visit at 120 days, the control group patients were given the choice to receive patient-appropriate treatment. The Crossover cohort is comprised of those patients who elected to cross over to receive stimulation

at a therapeutic level at the 120-day visit. Four patients in the Control Group had the device explanted prior to the 120-day visit (3 infections and 1 patient request due to lack of efficacy). All patients in the Control Group with a device implanted at 120 days chose to cross over.

A total of 102 patients were randomized in each study group in the ITT population (total 204 patients).

While the difference in responder rates grew over time between the Treatment group (57.1%) and the Control group (46.6%), it did not reach statistical significance (p=0.1377) (Table 9) at the 120-day primary endpoint visit.

Table 9: Responder Rate Low Back Pain VAS with No Increase in Pain Medications

Primary Efficacy Endpoint[1]	Treatment N=102 %	Control N=102 %	Difference p-value[2]
Responder (≥30% reduction in low back pain VAS and no increase in pain medications)	57.1%	46.6%	10.4% p=0.1377

[1] Results for 3 patients (2 Treatment, 1 Control) LTFU were included using multiple imputation.
[2] p-value is based on a Wald asymptotic test of proportions, with multiple imputation to handle missing values, and a Cui et al p-value adjustment.

Cumulative Proportion of Responders Analysis

The Cumulative Proportion of Responders Analysis (CPRA) is a method of evaluating patient responses over a full range of response levels, utilizing the same data as the primary endpoint. Rather than relying on one cut-point for evaluation, the CPRA provides a more accurate reflection of the full nature of the data.[iii] This method utilizes the Friedman's regression analysis, which is a comparison of ranks. This test preserves information over dichotomizing an endpoint, thereby improving statistical power.[iv,v,vi]

The CPRA, which was prespecified in the clinical protocol and SAP prior to the start of the trial, was performed using the same data as used for the primary endpoint analysis. The results of the CPRA (Figure 2) demonstrated a statistically significant difference between the Treatment group and the Control group (p=0.0499).

Notably, the Treatment group showed a higher percentage of responders across all threshold levels.



[1]MI (Rubin) for LTFU, Friedman's regression analysis & p-value for difference between groups. Since multiple imputation provides an overall group estimate, but not a specific estimate for each patient with missing data, these 3 patients that are LTF cannot be plotted in the figure; however, given the small amount of missing data, this is a very close approximation, and the 3 patients are accounted for in the p-value.

Figure 2: Cumulative Proportion of Responders in LBP VAS

Change in Mean VAS Analysis

In addition, the analysis of difference in mean LBP VAS reduction between the Treatment group and the Control group was statistically significant at the 120-day visit (p=0.032) (Table 10).

Table 10: VAS Results at Day 120

VAS Measure	Treatment N=100 Mean ± SD (min, max)	Control N=101 Mean ± SD (min, max)	Difference p-value[1]
Mean change in low back pain VAS	-3.3 ± 2.7 (-8.5, 3.0)	-2.4 ± 2.9 (-8.8, 3.5)	0.9 p=0.032

[1]Three patients were lost to follow-up (2 Treatment, 1 Control). Per the statistical analysis plan, secondary and supporting endpoints do not impute data for missing values. p-value is from a two-sample, two-sided t-test.

Components of the Primary Endpoint

VAS Component of the Primary Endpoint

When evaluating the VAS component of the primary endpoint (without taking into account pain medication changes), between-groups difference in proportion of patients with ≥30% reduction in LBP VAS grew over time but did not achieve statistical significance (Treatment: 58.8%, Control: 48.6%; p=0.1438). As with the primary endpoint, multiple imputation is utilized to account for missing data; therefore, this analysis is based on N=102 in both study groups.

Medication Component of the Primary Efficacy Endpoint

Data pertaining to all prescribed medications were collected at each scheduled follow-up visit. Patients were instructed to keep medications stable through the 120-day visit. If a medication was prescribed and taken for pain and was increased or added within the 2- week interval prior to the 120-day visit, the patient was counted as a treatment failure for the primary efficacy endpoint.

Nine patients in the Treatment group and nine patients in the Control group had increases in pain medications for any reason within the two-week window prior to the 120-day visit (Table 11), all of which were counted as treatment failures for the primary efficacy endpoint.

Table 11: Increases in Pain Medications at the 120-Day Visit

Reason for Increase	Treatment N=100 n	Control N=101 n
Low back pain	3	9
Reason unrelated to low back pain	6	0
Total	**9**	**9**

Of these 18 patients, 6 patients had increases in pain medications for the following reasons that were unrelated to LBP:

1. Broken ankle
2. Tooth extraction
3. Upper respiratory tract infection (URTI)
4. Anal abscess
5. Knee injury
6. Renal stone

Notably, all 6 of these patients were in the Treatment group.

In the Control group all 9 patients increased pain medications for LBP, as did the remaining 3 patients in the Treatment group. Three patients (1 in the Treatment group and 2 in the Control group) were on post-operative pain medications, and because the surgery was related to their LBP, they have been counted as medication increases related to LBP.

The adverse events were adjudicated by the Clinical Events Committee, and an independent organization reviewed the medication changes and the adverse events to confirm the accuracy of the categorizations. Change within the two-week window, indicate that the patient had taken the medication within the two-week window prior to the visit, but the patient was not taking the medication on the day of the visit.

Secondary Endpoints and Supporting Analyses

Data on all prespecified secondary endpoints were collected at the 120-day visit to compare changes from baseline in physical and social function (ODI), overall quality of life (EQ-5D), percent pain relief (PPR), resolution of low back pain, and subject global impression of change (SGIC) between the Treatment and Control groups. All patient questionnaires were administered prior to any interaction with the patient and prior to unblinding.

Since the primary endpoint did not meet statistical significance, hypotheses for the secondary endpoints were not to be formally tested. P-values are provided in this report for descriptive purposes only.

Statistical significance was reached for the comparison between the Treatment and Control groups on multiple secondary endpoints and supporting analyses at the 120-day visit (Table 12), demonstrating:

- Greater reduction in pain as measured by mean LBP VAS and PPR
- Greater improvement in physical and social function, including sleep, as measured by ODI, Cumulative Proportion of ODI Responders, and Ability to Work
- Greater improvement in overall quality of life as measured by EQ-5D
- Higher treatment satisfaction as measured by TSQ
- More favorable impression of change as measured by SGIC and CGI

Table 12: Secondary Efficacy Endpoints and Supporting Analyses

	Treatment		Control		
Endpoint	**N[1]**	**Mean ± SD (Min, Max) or n (%)**	**N[1]**	**Mean ± SD (Min, Max) or n (%)**	**Difference p-value[2]**
Change in Low Back Pain VAS	100	-3.3 ± 2.7 (-8.5, 3.0)	101	-2.4 ± 2.9 (-8.8, 3.5)	0.9 p = 0.032
Change in ODI	100	-17.5 ± 15.1 (-58.0, 20.0)	101	-12.2 ± 14.6 (-48.0, 32.0)	-5.4 p = 0.011
Change in EQ-5D	100	0.186 ± 0.199 (-0.365, 0.782)	100	0.115 ± 0.178 (-0.640, 0.665)	0.071 p = 0.009
Percent Pain Relief	100	52 ± 32 (0, 100)	101	35 ± 36 (0, 100)	17 p < 0.001
Subject Global Impression of Change					
Much Better	100	32 (32%)	101	18 (18%)	NA p = 0.003
Better	100	22 (22%)	101	16 (16%)	
A Little Better	100	25 (25%)	101	29 (29%)	
No Change	100	10 (10%)	101	24 (24%)	
A Little Worse	100	6 (6%)	101	5 (5%)	
Worse	100	4 (4%)	101	6 (6%)	
Much Worse	100	1 (1%)	101	3 (3%)	
Resolution of Back Pain (VAS ≤ 2.5)	100	34 (34%)	101	28 (28%)	6.3% p = 0.335
Satisfied with Treatment					
Definitely Yes	100	61 (61%)	101	40 (40%)	p < 0.001
Maybe	100	29 (29%)	101	37 (37%)	
Definitely Not	100	10 (10%)	101	24 (24%)	
Clinician Global Impression					
Much Better	100	57 (57%)	100	22 (22%)	p < 0.001
Slightly Better	100	26 (26%)	100	29 (29%)	
About the Same	100	16 (16%)	100	42 (42%)	
Slightly Worse	100	1 (1%)	100	5 (5%)	
Much Worse	100	0 (0%)	100	2 (2%)	

[1] 3 patients were lost to follow-up (2 Treatment, 1 Control). 1 patient in the Control group did not complete all sections of the EQ-5D questionnaire; therefore, no score could be completed. Per the SAP, secondary endpoints do not impute data for missing values.

[2] For continuous variables the p-value is from a two-sample, two-sided t-test; for SGIC p-value is from Mann-Whitney; for TSQ and CGI p-value is from Cochran-Mantel-Haenszel, and for Resolution of Back Pain p-value is from Chi-square test.

Long Term Results

All efficacy outcome measures progressively improved through the two-year visit, consistent with the rehabilitative nature of the therapy (Table 13). One-year data was collected for 176/204 patients, and two-year data was collected for 156/204 patients. The imputation method for missing data was stratified based on randomness and the reason for missing data. Baseline observation carried forward (BOCF) was used for participants withdrawn for reported lack of efficacy at any time, or permanent explant after infection. For those withdrawn for reasons unrelated to lack of efficacy (i.e., precautionary device removal for MRI or resolution of pain, a move out of state or loss to follow-up) and random missed visits, the mixed-effects model repeated measures (MMRM) approach was used to provide implicit imputations of missing data. The MMRM included available intermediate data and relevant baseline covariates including the baseline value of patient reported outcomes.

Table 13: Summary of Endpoints at One and Two years – Treatment Groups Combined

Analysis	Baseline	Year 1		Year 2	
	Mean ± SD	Mean (SE) or % (n/N) (95% CI)	Mean (SE) or % (n/N) (95% CI)	Mean (SE) or % (n/N) (95% CI)	Mean (SE) or % (n/N) (95% CI)
	N=204	As Reported N=176	Imputed N=204	As Reported N=156	Imputed N=204
LBP VAS	7.3 ± 0.7	3.0 (0.2)	3.4 (0.2)	2.4 (0.2)	3.1 (0.2)
Change from BL		-4.3 (0.2) (-4.7, -3.9)	-3.9 (0.2) (-4.3, -3.6)	-4.8 (0.2) (-5.2, -4.5)	-4.2 (0.2) (-4.6, -3.8)
Resolution of LBP		52 (91/176) (44, 60)	48 (4) (41, 55)	67 (103/155) (59, 74)	58 (4) (51, 65)
ODI	39.1 ± 10.3	19.0 (1.4)	20.7 (1.0)	17.6 (1.2)	20.2 (1.0)
Change from BL		-19.9 (1.2) (-22.3, -17.6)	-18.4 (1.0) (-20.4, -16.4)	-21.4 (1.3) (-24.0, -18.7)	-18.9 (1.0) (-21.0, -16.8)
EQ-5D	0.585 ± 0.174	0.780 (0.012)	0.762 (0.011)	0.798 (0.013)	0.768 (0.011)
Change from BL		0.198 (0.016) (0.167, 0.229)	0.177 (0.011) (0.156, 0.199)	0.218 (0.017) (0.184, 0.253)	0.183 (0.011) (0.161, 0.205)
PPR		66 (2) (61, 71)	61 (3) (56, 66)	72 (2) (67, 77)	62 (3) (57, 67)
SGIC (Better or Much Better)		72 (126/176) (65, 78)	66 (3) (59, 73)	79 (121/154) (72, 85)	69 (3) (62, 75)
TSQ (Definitely Satisfied)		78 (136/174) (72, 84)	72 (3) (66, 78)	80 (124/155) (74, 86)	68 (3) (62, 75)
CGI		73 (129/176) (67, 80)	68 (3.4) (61, 74)	78 (119/152) (72, 85)	67 (3.6) (60, 74)

Pain and Function

The protocol specified a threshold of ≥30% improvement on LBP VAS for the primary endpoint (per IMMPACT and FDA recommendations). Other commonly reported thresholds for "success" are ≥50% improvement on LBP VAS and absolute LBP VAS scores of ≤2.5 cm (commonly referred to as "Remitter" or "Resolution").

Similarly, the protocol specified a threshold of ≥10 points improvement on ODI as a clinically meaningful change. Other commonly reported thresholds for "success" are ≥15 points and ≥20 points improvements on the ODI scale.

The longitudinal "success rates" using these commonly reported thresholds are summarized in a and b. For these graphical representations, changes in pain medications were not considered.



Figure 3: Longitudinal "Success Rates" in Treatment Groups Combined (a) VAS and (b) ODI

Patients suffering from CLBP are continuously balancing their activity level with their level of pain. As their condition improves, patients make personal choices on whether to increase their level of activity while tolerating a certain level of pain, or to continue with the same level of activity as earlier but with less pain, or somewhere in between. These choices are based on the patients' individual circumstances and preferences. Therefore, when evaluating a therapy for CLBP, improvements in pain should be interpreted in conjunction with functional improvements, to obtain a complete picture of the benefit provided by the therapy.

ReActiv8 is a rehabilitative therapy and progressive improvement can be expected over time, both in magnitude of effect and the proportion of patients who benefit from the treatment. It is hence informative to review the two-year data for the magnitude and durability of effect.

Figure 4 below shows the effect of ReActiv8 therapy as a combination of pain and disability on individual patients.



Figure 4: Longitudinal "Success Rates" in Treatment Groups Combined in LBP VAS and/or ODI

At the two-year visit, 77% of patients reported a substantial[vii] improvement in pain, as measured by LBP VAS, and improvement in physical and social function, as measured by ODI over baseline, or both of these measures (Figure 4). These data suggest that the vast majority of patients have gained increased ability to manage their daily activities.

Changes in Opioid Use

Of the 65 patients (Treatment and Crossover groups combined) who were on at least one opioid-containing medication at baseline and had a one-year visit, 48% had discontinued or decreased opioid use (Table 14). These trends continue through the two-year visit. The patients who decreased or discontinued opioids had been taking opioids for an average of 4 ± 5 years. In addition, 97% of those who were not on an opioid at baseline remained off opioids at the one-year visit, and 96% remained off opioids at the two-year visit.

Table 14: Changes in Opioids at One and Two Years for Treatment Groups Combined

Opioid Change Status	1 Year		2 Years	
	N	Change in Opioid Use n (%)	N	Change in Opioid Use n (%)
On Opioids at Baseline				
Discontinued or Decreased	65	31 (48%)	57	34 (60%)
No Change	65	29 (45%)	57	22 (39%)
Increased	65	5 (8%)	57	1 (2%)
Not on Opioids at Baseline				
Remained Off at Annual Follow-up	111	108 (97%)	98	94 (96%)
Added	111	3 (3%)	98	4 (4%)

Similarly, when looking at pain medications of any class, discontinued or decreased use is seen over time, and 85% of patients who were not on pain medications at baseline remain off pain medications at the two-year visit.

Table 15: Changes in Pain Medications at One and Two Years for Treatment Groups Combined

Pain Medication Change Status	1 Year		2 Years	
	N	Change in Opioid Use n (%)	N	Change in Opioid Use n (%)
On Pain Medications at Baseline				
Discontinued or Decreased	139	76 (55%)	122	80 (66%)
No Change	139	53 (38%)	122	36 (30%)
Increased	139	10 (7%)	122	6 (5%)
Not on Pain Medications at Baseline				
Remained Off at Annual Follow-up	37	32 (86%)	33	28 (85%)
Added	37	5 (14%)	33	5 (15%)

Summary

These results are achieved with a therapy that, by its design, is restorative in nature and takes time for its restorative effect to be achieved. Patients have shown substantial benefits from ReActiv8 therapy, and those benefits have expanded over time: by the two year follow-up visit, the mean improvement in VAS pain from baseline is 4.8 cm, the mean ODI improvement is 21 points, 79% of patients report feeling “much better” or “better”, and 80% of patients report being “definitely satisfied” with the treatment (Figure 5).

Treatment Control Combined

30% Responder Rate (Primary)
- Day 120: **p=0.138**
- 1 Year: 66%
- 2 Years: 74%

Mean Reduction in LBP VAS
- Day 120: **p=0.032**
- 1 Year: 4.3cm
- 2 Years: 4.8cm

VAS 30% Responder Rate (Primary)



Mean Reduction in LBP VAS



Resolution of Back Pain
- Day 120: **p=0.335**
- 1 Year: 52%
- 2 Years: 66%

Percent Pain Relief
- Day 120: **p<0.001**
- 1 Year: 66%
- 2 Years: 72%

Resolution of Back Pain



Percent Pain Relief



ODI
- Day 120: **p=0.011**
- 1 Year: 20-pt
- 2 Years: 21-pt

EQ-5D
- Day 120: **p=0.009**
- 1 Year: 0.198
- 2 Years: 0.217

ODI



EQ-5D



SGIC (Better or Much Better)
- Day 120: **p=0.003**
- 1 Year: 72%
- 2 Years: 79%

CGI (Much Better)
- Day 120: **p<0.001**
- 1 Year: 73%
- 2 Years: 78%

SGIC



CGI



TSQ (Satisfied)
- Day 120: **p<0.001**
- 1 Year: 78%
- 2 Years: 80%

TSQ



For continuous the p-value from a two-sample, two-sided t-test; for SGIC p-value is from Mann-Whitney; for TSQ and CGI p-value is from Cochran-Mantel-Haenszel, and for Resolution of Back Pain p-value is from Chi-square test.

Figure 5: Summary of Efficacy Data through Two Years

I. SUMMARY OF CLINICAL INFORMATION

The ReActiv8-B study was an international, multi-center, prospective, randomized, blinded trial comparing the ReActiv8 System programmed to therapeutic stimulation settings (Treatment group) to the ReActiv8 system programmed minimal stimulation active sham settings (Control group). Although the primary efficacy endpoint was inconclusive at the 120-day visit, the totality of evidence provides compelling support in favor of the treatment. The prespecified cumulative proportion of responder analysis of the primary endpoint data (ITT) showed that the difference between the Treatment and Control group was statistically significant (p=0.0499).

Patients in the trial had an average CLBP duration of 14 years and suffered pain on 97% of the days in the year prior to enrolment. The overall results demonstrated that patients moved from severe pain and borderline severe disability to mild pain and disability. Benefits which emerged in favor of the treatment within the blinded phase continued to grow through the two-year visit, demonstrating durability of the gained improvements and corroborating the rehabilitative nature of the treatment. The reversal of trajectory and subsequent substantial and significant improvements documented in the Control group post crossover at 120 days, provides further support in favor of ReActiv8 treatment efficacy.

Clinically meaningful and durable improvements were consistently demonstrated across all outcome measures and 60% of patients who were on opioids at baseline, had discontinued or reduced their use by the two-year visit.

Given the public health concern over the chronic use of opioids, physicians and patients are looking for non-opioid options for treating pain, and this data supports that ReActiv8 is a safe, effective and durable nondrug treatment option for mechanical CLBP.

The consistent clinically meaningful benefits across all outcome measures, the favorable safety profile and positive impact on opioid reduction demonstrated in this trial, leads to a favorable benefit/risk ratio for use of this therapy in severely impacted patients with refractory mechanical CLBP.

A. Effectiveness Conclusions

Effectiveness for the ReActiv8 System was based on Level 1 evidence from the ReActiv8-B pivotal trial. Two-hundred and four (204) patients were implanted with the ReActiv8 System and randomized to the Treatment group (102) and the Control group (102). Although the primary efficacy endpoint was inconclusive at the 120-day visit, the totality of evidence provides compelling support in favor of the treatment. The cumulative proportion of responder analysis on the same (ITT) primary endpoint data demonstrated a significant difference (p=0.0499) between the Treatment and Control

group.

Moreover, statistical significance was reached for the comparison between the Treatment and Control groups on multiple secondary effectiveness endpoints and supporting analyses at the 120-day visit (Table 12), demonstrating:

- Greater reduction in pain as measured by mean LBP VAS and PPR
- Greater improvement in physical and social function, including sleep, as measured by ODI, Cumulative Proportion of ODI Responders, and Ability to Work
- Greater improvement in overall quality of life as measured by EQ-5D
- Higher treatment satisfaction as measured by TSQ
- More favorable impression of change as measured by SGIC and CGI

Benefits which emerged in favor of the treatment within the blinded phase continued to grow through the two-year visit, demonstrating durability of the gained improvements and corroborating the rehabilitative nature of the treatment. The two- year data across all pre-specified endpoints demonstrated reduced pain, increased physical and social function, improved quality of life, positive subject and clinician impression of change, and high overall treatment satisfaction.

The pre-specified secondary analysis of primary and secondary efficacy outcomes in the Control Group after cross-over to therapeutic stimulation at the 120-day visit, demonstrated clinically relevant and statistically significant improvements over and above the greater than expected sham-response. These improvements continued to grow through two years, providing further support in favor of the treatment.

B. Safety Conclusions

The risk assessment of the device is based on nonclinical laboratory testing, animal studies, previous ReActiv8 clinical trials, published literature as well as data collected in the ReActiv8-B clinical study conducted to support PMA approval as described above. SAEs related to the device or procedure occurred in 4% of the 204 implanted patients and all but one resolved. No deaths occurred in the study. There were no unanticipated adverse device effects (UADE).

Because the control group also received the implanted ReActiv8 system as an active sham, similar active implantable neurostimulation systems such as Spinal Cord Stimulation (SCS) systems provide a more relevant context for the safety profile, even though the treated population is different.

Across the common risks associated with neurostimulation systems, the ReActiv8 safety profile compares favorably to the published SCS experience. Notably no lead migrations occurred in the ReActiv8-B trial.

Most adverse events occurred within the 120-day period, with similar related adverse event rates in both study groups (36% of the Treatment patients versus 34% of Control patients). The most commonly reported adverse events are: 1) implant site pain/discomfort (18%) most of which resolved within days or weeks after implant without intervention; 2) device overstimulation (13%) that was typically resolved with reprogramming of the device; 3) lead conductor fractures requiring lead replacements (4%); 4) surgical pocket infection (3%) all of which were resolved with explant of the system and antibiotics. These reported rates are within the range of published rates for SCS therapy.

C. Benefit-Risk Conclusions

The probable benefits of the device are based on the clinical study described above. Effectiveness of the ReActiv8 system was demonstrated by the totality of evidence observed. Benefits observed in all pre-specified endpoints continued to grow through two years. One- and two-year results consistently show that patients have reduced pain, increased physical and social function, improved quality of life, positive subject and clinician impression of change, and high overall treatment satisfaction.

D. Overall Conclusions

The data in this application support the reasonable assurance of safety and effectiveness and a favorable clinical benefit to risk determination of this device when used in accordance with the indications for use. The results from comprehensive pre-clinical testing show that the ReActiv8 System performs as intended. Results from the ReActiv8-B sham-controlled, double-blinded pivotal study, prior published studies and reported clinical experience support the safety and effectiveness of the ReActiv8 System.

Although the primary efficacy endpoint was inconclusive at the 120-day visit, the totality of evidence provides compelling support in favor of the treatment. The cumulative proportion of responder analysis on the same (ITT) primary endpoint data demonstrated a significant difference (p=0.0499) between the Treatment and Control group. In addition, the Supplementary Analysis, which removed the confounding factor of increase in pain medications for reasons other than back pain, also demonstrated a statistically significant difference.

Moreover, statistical significance was reached for the comparison between the Treatment and Control groups on multiple secondary effectiveness endpoints and supporting analyses at the 120-day visit (Table 12), demonstrating:

- Greater reduction in pain as measured by mean LBP VAS and PPR

- Greater improvement in physical and social function, including sleep, as measured by ODI, Cumulative Proportion of ODI Responders, and Ability to Work
- Greater improvement in overall quality of life as measured by EQ-5D
- Higher treatment satisfaction as measured by TSQ
- More favorable impression of change as measured by SGIC and CGI

The benefits observed during the blinded study phase, continued to grow through two years, consistent with the restorative nature of the therapy. Across all pre-specified endpoints, the two-year data demonstrated that patients have reduced pain, increased physical and social function, improved quality of life, positive subject and clinician impression of change, and high overall treatment satisfaction.

The pre-specified secondary analysis of primary and secondary efficacy outcomes in the Control Group after cross-over to therapeutic stimulation at the 120-day visit, demonstrated clinically relevant and statistically significant improvements over and above the greater than expected sham-response. These improvements continued to grow through two years, providing further support in favor of the treatment.

Clinically relevant and statistically significant improvements were observed between 120 days and two years on all primary and secondary efficacy outcomes in the Control group following crossover to therapeutic treatment levels with 8 months of active therapy. This was in addition to the (greater than expected) improvements recorded under sham conditions, providing further support in favor of the treatment. The study also proved meaningful discontinuation and reduction in opioid use at the two-year visit

As described above, ReActiv8 was determined to be safe. The adverse events that were reported were consistent and many favorable to well-known safety profile of marketed SCS systems as described in the literature.

The totality of evidence generated by the ReActiv8-B trial demonstrated a favorable benefit-risk profile which is appropriate in therapies for patients with intractable mechanical CLBP.

---

[i] Hayek, S.M., Veizi, E., Hanes, M. Treatment-Limiting Complications of Percutaneous Spinal Cord Stimulator Implants: A Review of Eight Years of Experience from an Academic Center Database. *Neuromodulaton* (2015).

[ii] Eldabe, S., Buchser, E., Duarte, R.V., Complications of Spinal Cord Stimulation and Peripheral Nerve Stimulation Techniques: A Review of the Literature. *Pain Medicine* (2015).

[iii] Ferrar JT, Dworkin RH, Mitchell BM Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over Range of Cut-Off Points: Making Clinical Trial Data More Understandable. *J Pain Symptom Manage* 2006;31:369-377.

[iv] Cappelleri, Joseph C; Zou, Kelly H; Bushmakin, Andrew G; Alvir, Jose Ma. J; Alemayehu, Demissie; Symonds, Tara. *Patient-Reported Outcomes, Measurement, Implementation and Interpretation*. CRC Press, 2014.

[v] Senn, S., Julious, S., Measurement in clinical trials: A neglected issue for statisticians? *Statist. Med.* 28:3189-3209 (2009).

[vi] Federov, V., Mannino, F., Zhang, R. Consequences of dichotomization. *Pharmaceut. Statist.* 8:50-61 (2009).

[vii] Chou, R., Loeser, J.D., Owens, D.K., Rosenquist, R.W., Atlas, S.J., Baisden, J., et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine* (Phila Pa 1976) [Internet]. May;34(10):1066-77 (2009).